224 related articles for article (PubMed ID: 15283986)
1. Biomarker discovery and validation: technologies and integrative approaches.
Ilyin SE; Belkowski SM; Plata-Salamán CR
Trends Biotechnol; 2004 Aug; 22(8):411-6. PubMed ID: 15283986
[TBL] [Abstract][Full Text] [Related]
2. Computational biology for cardiovascular biomarker discovery.
Azuaje F; Devaux Y; Wagner D
Brief Bioinform; 2009 Jul; 10(4):367-77. PubMed ID: 19276200
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
Phan JH; Quo CF; Wang MD
Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
[TBL] [Abstract][Full Text] [Related]
5. Quantitative proteomics for drug toxicity.
Gao Y; Holland RD; Yu LR
Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
[TBL] [Abstract][Full Text] [Related]
6. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis.
Villoslada P; Baranzini S
J Neuroimmunol; 2012 Jul; 248(1-2):58-65. PubMed ID: 22281286
[TBL] [Abstract][Full Text] [Related]
7. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
8. Approaching clinical proteomics: current state and future fields of application in cellular proteomics.
Apweiler R; Aslanidis C; Deufel T; Gerstner A; Hansen J; Hochstrasser D; Kellner R; Kubicek M; Lottspeich F; Maser E; Mewes HW; Meyer HE; Müllner S; Mutter W; Neumaier M; Nollau P; Nothwang HG; Ponten F; Radbruch A; Reinert K; Rothe G; Stockinger H; Tárnok A; Taussig MJ; Thiel A; Thiery J; Ueffing M; Valet G; Vandekerckhove J; Wagener C; Wagner O; Schmitz G
Cytometry A; 2009 Oct; 75(10):816-32. PubMed ID: 19739086
[TBL] [Abstract][Full Text] [Related]
9. Proteomics: new technologies and clinical applications.
Latterich M; Abramovitz M; Leyland-Jones B
Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
[TBL] [Abstract][Full Text] [Related]
10. [Biomarkers: "Found in translation"].
Lockhart BP; Walther B
Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
[TBL] [Abstract][Full Text] [Related]
11. Translation of neurological biomarkers to clinically relevant platforms.
Hayes RL; Robinson G; Muller U; Wang KK
Methods Mol Biol; 2009; 566():303-13. PubMed ID: 20058180
[TBL] [Abstract][Full Text] [Related]
12. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
13. Cancer biomarkers: current issues and future directions.
Jain KK
Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
[TBL] [Abstract][Full Text] [Related]
14. Label-free mass spectrometry-based proteomics for biomarker discovery and validation.
Pham TV; Piersma SR; Oudgenoeg G; Jimenez CR
Expert Rev Mol Diagn; 2012 May; 12(4):343-59. PubMed ID: 22616700
[TBL] [Abstract][Full Text] [Related]
15. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
16. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
Calvo KR; Liotta LA; Petricoin EF
Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
[TBL] [Abstract][Full Text] [Related]
17. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
18. Role of oncoproteomics in the personalized management of cancer.
Jain KK
Expert Rev Proteomics; 2004 Jun; 1(1):49-55. PubMed ID: 15966798
[TBL] [Abstract][Full Text] [Related]
19. Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.
Gundert-Remy U; Dahl SG; Boobis A; Kremers P; Kopp-Schneider A; Oberemm A; Renwick A; Pelkonen O
Toxicol Lett; 2005 Apr; 156(2):227-40. PubMed ID: 15737486
[TBL] [Abstract][Full Text] [Related]
20. Protein biomarkers for in vitro testing of toxicology.
Schrattenholz A; Šoškić V; Schöpf R; Poznanović S; Klemm-Manns M; Groebe K
Mutat Res; 2012 Aug; 746(2):113-23. PubMed ID: 22405942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
